Agile Therapeutics, headquartered in Princeton, New Jersey, is dedicated to fulfilling the unmet health needs of women by developing and commercializing new prescription contraceptive products. Their lead product candidate, Twirla, is a once-weekly contraceptive patch that delivers a combination of hormonal contraceptives through the skin. Agile Therapeutics has secured significant funding through multiple series rounds and a private placement agreement, allowing them to advance their innovative transdermal patch technology called Skinfusion. Their goal is to provide women with contraceptive options that offer convenience and improved adherence.